

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

**SANGAMO BIOSCIENCES NAMES JULIE WOOD
TO HEAD CORPORATE COMMUNICATIONS**

Point Richmond, California – April 12, 2000 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the appointment of Julianna Wood as senior director of corporate communications. Wood will be responsible for all external communications, including investor relations and public affairs. In this newly created position, she will report to Edward Lanphier, Sangamo’s president and chief executive officer.

Most recently Wood was senior director of corporate communications and investor relations at Chiron Corporation, a leading biotechnology company. Prior to Chiron, she served as a communications consultant to healthcare companies. Wood has also held similar communications positions with other biotechnology companies, including Glycomed Incorporated and Somatix Therapy Corporation.

“Julie brings to Sangamo a broad array of skills and a comprehensive knowledge of the biotechnology sector,” said Edward Lanphier. “With her corporate experience, she is well versed in the issues that face newly public companies. Effective communication is an important priority for Sangamo, and Julie will play a key role in defining and articulating our corporate messages.”

Wood has been actively involved in the healthcare industry since the early 1980’s. During that time she has taken on increasing levels of management responsibility across a variety of corporate functions, including investor relations, corporate communications, and marketing. Wood earned her undergraduate degree from Stanford University and has a M.B.A. from Duke University.

Sangamo is focused on the research and development of novel transcription factors for the regulation of genes. Genes are composed of DNA and control the expression and transmission of all inherited traits. Transcription factors are proteins that turn genes on and turn genes off, or regulate gene expression, by recognizing specific DNA sequences. Sangamo’s Universal Gene Recognition technology enables the engineering of transcription factors known as zinc finger DNA binding proteins, or ZFPs. ZFPs are the most abundant class of transcription factors in humans and other higher organisms and naturally function to regulate gene expression. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, therapeutics for the treatment of human diseases, clinical diagnostics, and agricultural and industrial biotechnology.

-more-

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Those forward-looking statements include statements related to the ability of Sangamo BioSciences, Inc. to continue to meet marketing, technology, and customer demands as it relates to its products within the gene regulation market. Actual results may differ materially due to a number of factors, including numerous technological, operational and financial challenges associated with the regulation of genes. The matters discussed in this press release also involve risks and uncertainties concerning Sangamo's products and services described in Sangamo's filing on Form S-1 with the SEC. In particular, see the risk factors described in the company's Registration Statement on Form S-1 filed with the SEC. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

Contacts: Edward Lanphier
Sangamo BioSciences, Inc.
510-970-6000, x207
lanphier@sangamo.com

Julie Wood
Sangamo BioSciences, Inc.
510-970-6000, x256
jwood@sangamo.com

Amy Giller
Noonan/Russo Communications
415-677-4455, x206
a.giller@noonanrusso.com

###